Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Berberine · 1 trial · 3 indications
Assessments will be conducted at baseline and once every three weeks thereafter.
| Arm | Type | Description |
|---|---|---|
| Berberine | ACTIVE_COMPARATOR | Patients will receive berberine pills in additional to current atypical antipsychotic agents |
| Placebo | PLACEBO_COMPARATOR | Patients will receive placebos pills in additional to current atypical antipsychotic agents |
| Name | Type | Description |
|---|---|---|
| Berberine | DRUG | Berberine tablets, 0.3g every time, two times daily |
| Placebos | DRUG | Placebo tablets, 0.3g every time, two times daily |
| Antipsychotic Agents | DRUG | Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study. |
Inclusion Criteria: * a primary diagnosis of SSD, including schizophrenia, schizoaffective disorder, schizophreniform disorder, and psychotic disorder not otherwise specified according to the Classification of Mental and Behavior Disorders (10th version); * have been under atypical antipsychotic tr...
Berberine is an investigational small molecule being studied as an adjuvant treatment for schizophrenia. In a Phase 2 clinical trial, it was evaluated in patients with schizophrenia, schizophrenia spectrum and other psychotic disorders, and metabolic syndrome. The study has been completed.
Berberine is a small molecule being developed by Castle Biosciences, Inc. for use in schizophrenia. The specific molecular target of berberine is not disclosed in the available information. It is being studied as an adjunctive treatment in patients with schizophrenia and metabolic syndrome.
Berberine is being developed by Castle Biosciences, Inc., a company traded on the stock exchange under the ticker symbol CSTL. The company is conducting clinical research on berberine as a potential treatment for schizophrenia.
Berberine is in Phase 2 clinical development. A Phase 2 clinical trial has been completed, evaluating berberine as an adjuvant treatment for schizophrenia patients. The drug is investigational and has not been approved by regulatory authorities.
Berberine has one completed clinical trial registered under NCT02983188, titled 'Berberine as Adjuvant Treatment for Schizophrenia Patients'. This Phase 2 study enrolled 113 participants in Hong Kong and was a randomized, double-blind, placebo-controlled trial.
Berberine is a naturally occurring compound found in several plants, including goldenseal, barberry, and tree turmeric. It is also known by the chemical name berberine hydrochloride. In the context of this clinical trial, it is being studied as a supplement for schizophrenia treatment.